Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiff Oncology, Inc. filings document regulatory disclosures for a clinical-stage oncology company developing onvansertib and PLK1-inhibition programs. Recent Form 8-K reports cover financial results, business updates, Regulation FD presentation materials, CRDF-004 clinical disclosures in first-line RAS-mutated metastatic colorectal cancer and other material events tied to the company's development strategy.
The company's proxy and current reports also address board and executive governance, officer appointments and departures, separation agreements, compensation arrangements, equity awards and Nasdaq inducement grants. These filings include formal disclosure of risk themes common to clinical-stage biotechnology issuers, including clinical-trial uncertainty, financing needs, dependence on key personnel and operating disruptions.
Cardiff Oncology, Inc. (CRDF) – Form 4 filing dated 06/30/2025
The filing discloses that director Rodney S. Markin received 40,565 stock options on 06/26/2025 at an exercise price of $3.16 per share. The options become exercisable on 06/26/2026 and expire on 06/26/2035. The transaction is coded “A,” indicating an award or grant with no cash paid by the insider. Following the grant, Markin holds 222,865 derivative securities (stock options) directly. No open-market purchases or sales of common stock were reported, and no changes were recorded in Markin’s non-derivative share ownership.
The grant is a routine equity incentive intended to align the director’s interests with those of shareholders. Given the modest size relative to Cardiff Oncology’s total shares outstanding, the transaction is considered immaterial from a dilution standpoint and does not, by itself, signal any change to the company’s strategic outlook or financial condition.
Cardiff Oncology director James O. Armitage received a new stock option grant on June 26, 2025. The derivative securities transaction details include:
- Granted 40,565 stock options to purchase common stock
- Exercise price set at $3.16 per share
- Options become exercisable on June 26, 2026
- Options expire on June 26, 2035
- Following this grant, Armitage now beneficially owns 187,539 derivative securities directly
This Form 4 filing represents a standard director compensation stock option grant, which vests one year from the grant date and has a 10-year exercise period. The transaction appears to be part of the company's regular director compensation program rather than an open market transaction.
On 06/26/2025, Cardiff Oncology (CRDF) director Lale White reported the grant of 40,565 stock options at an exercise price of $3.16 under Form 4. The options become exercisable on 06/26/2026 and expire on 06/26/2035. The transaction code "A" confirms the award was acquired rather than purchased on the open market. Following this grant, White now holds 158,681 derivative securities (options) directly. No common shares were bought or sold, and no additional non-derivative activity was disclosed.
This filing appears to reflect routine director compensation designed to align insider incentives with shareholder interests. Because the award involves options—requiring future exercise—there is no immediate cash outflow or direct impact on outstanding share count.
Cardiff Oncology, Inc. (CRDF) – Form 4 Overview
On 06/26/2025, Director Gary W. Pace received a grant of 40,565 stock options with an exercise price of $3.16 per share under the company’s equity compensation plan. The options expire on 06/26/2035. After the grant, Mr. Pace beneficially owns 187,539 derivative securities (options) in total. The Form 4, filed on 06/27/2025, reports no open-market purchases or sales of common stock, and the holdings are reported as Direct (D) ownership. This filing reflects routine director compensation rather than an investment decision.
Cardiff Oncology (Nasdaq:CRDF) filed a Form 8-K detailing the 26 June 2025 Annual Meeting vote results.
- All seven director nominees were elected with roughly 20.5-21.2 M votes in favor and no votes against.
- Shareholders ratified BDO USA, P.C. as the independent auditor for FY 2025 (36.3 M for, 1.2 M against, 1.1 M abstain).
- An amendment raising the 2021 Equity Incentive Plan’s share reserve to 12.15 M shares passed (16.9 M for, 5.0 M against).
- The advisory say-on-pay resolution was approved (18.9 M for, 2.6 M against).
No other material business or operational updates were disclosed.